Medpace Holdings, Inc. Website

Medpace Holdings, Inc.

NasdaqGS-MEDP

Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

  • Name

    Medpace Holdings, Inc.

  • CEO

    August James Troendle

  • Website

    www.medpace.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1992

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.

  • Medpace's operational discipline should support strong long-term earnings growth and high returns as the company continues to expand.

  • Medpace is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.

Bears Say

  • Significant pullbacks in biotech funding or declines in outsourcing penetration rates could have a material impact on Medpace's growth.

  • Large cancelations and potential pipeline reprioritizations from its customers could negatively affect Medpace.

  • Medpace could fail to innovate and keep an edge over regional and global CRO competitors, especially as data and analytics play an increasing role in clinical development.

Source: Morningstar Analysis - Oct 24, 2025

What's happening

Nov 13, 2025 - Dec 13, 2025

Insider Selling Weighs Heavily on Medpace Holdings Inc. Performance

  • Significant insider selling raised concerns about executive confidence in Medpace's future.
  • Chairman August J. Troendle divested over $62 million in shares, contributing to downward pressure on stock prices.
  • Despite some positive signals, the overall sentiment remained bearish due to continued executive sell-offs.

Over the past month, Medpace Holdings Inc. (MEDP) experienced a decline of 6.7%. This performance starkly contrasts with the S&P 500, which saw only a minimal drop of 0.2%. The notable decline was largely attributed to substantial insider selling that sparked investor concerns regarding the company's future prospects and executive confidence.

The trend of insider selling became prominent around late November when Chairman Troendle sold multiple batches of shares at varying prices, leading to increased downward pressure on MEDP's stock price. These transactions coincided with broader market activity characterized by cautious investor sentiment due to internal actions at Medpace, resulting in bearish movements across several trading days.

While there were moments indicating potential growth—such as Vice President Burwig acquiring additional shares—these instances were overshadowed by widespread negative sentiment stemming from extensive executive sell-offs. Although Burwig’s acquisition was perceived positively, it did not sufficiently counteract the prevailing impact of these sales dominating discussions surrounding MEDP’s performance.

On November 24th, positive commentary regarding Medpace’s operational capabilities and institutional ownership provided brief relief for investors; however, this momentum could not be sustained as subsequent trading sessions reflected ongoing bearish trends driven primarily by continued insider transactions and lackluster market conditions overall. Ultimately, while there were fleeting signs of stability for Medpace Holdings Inc., they were eclipsed by significant executive sell-offs that contributed heavily to its underperformance relative not only to the S&P 500 but also against its sector peers in Health Care (XLV), where it lagged behind by an alarming margin of 7.5%.

Medpace Holdings Inc underperformed the Health Care (XLV) sector by -7.5%.

NasdaqGS:MEDP